Clearmind Medicine Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CMND research report →
Price Chart
About the company
Clearmind Medicine Inc. is a pre-clinical biopharmaceutical company dedicated to pioneering the development of novel psychedelic-based treatments. Their primary goal is to address a variety of mental health and addiction challenges that currently lack adequate solutions.
- CEO
- Adi Zuloff-Shani
- IPO
- 2022
- Employees
- 4
- HQ
- Vancouver, BC, CA
Get TickerSpark's AI analysis on CMND
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.33M
- P/E
- -0.03
- PEG
- 0.00
- P/S
- 0.00
- P/B
- 0.04
- EV/EBITDA
- 1.08
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -87.29%
- ROIC
- -60.10%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-49,364+3.3%
- Op Income
- $-5,666,653
- Net Income
- $-3,856,627+26.6%
- EPS
- $-24.24+55.3%
- OCF Growth
- +30.0%
- FCF Growth
- +30.0%
- 52W High
- $649.60
- 52W Low
- $2.63
- 50D MA
- $5.82
- 200D MA
- $34.04
- Beta
- -1.21
- RSI (14)
- 13
- Avg Volume
- 55.57K
No earnings-call transcripts are available for CMND yet.
- Free Float
- 77.6%
- Shares Outstanding
- 507.40K
- Float Shares
- 393.87K
of shares held by institutions
2 13F filers
Buy/sell ratio 0.25. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 16, 26 | HRT FINANCIAL LP | sell | 22,139 |
| Jun 15, 26 | HRT FINANCIAL LP | sell | 3,183 |
| Jun 12, 26 | HRT FINANCIAL LP | sell | 2,102 |
| Jun 10, 26 | HRT FINANCIAL LP | buy | 2,159,052 |
| Jun 11, 26 | HRT FINANCIAL LP | sell | 225,191 |
| Jun 10, 26 | HRT FINANCIAL LP | other | 0 |
| May 12, 17 | Lamadrid David | other | 857,143 |
| May 1, 17 | Lamadrid David | other | 0 |
| May 1, 17 | Lamadrid David | other | 0 |
| May 1, 17 | Lamadrid David | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CMND coverage
Recent articles, reports, and earnings notes.
No research on CMND yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CMND report →Clearmind Medicine Expands PTSD Patent Portfolio with Hong Kong Patent Application Publication
globenewswire.com · Nov 19
Clearmind Achieves Full Enrollment for Part C in CMND-100 Phase I/IIa Trial, Marking Key Clinical Milestone
globenewswire.com · Nov 16
Clearmind Medicine Among Top Biopharma Companies Invited to join Washington DC, Psychedelic Summit
globenewswire.com · Nov 10
Clearmind Successfully Completes Patient Recruitment for the First Alcohol Use Disorder Cohort of its CMND-100 Phase I/IIa Clinical Trial
globenewswire.com · Oct 27
Clearmind: Charging Robotics Launches Next-Generation Automated EV-Charging Technology for Robotaxis and Autonomous Fleets
globenewswire.com · Oct 12
Clearmind Announces Patent Publication in Japan Covering Treatment for Neurological Movement Disorder
globenewswire.com · Oct 8
Clearmind Advances Dialogue with U.S. Federal Government on Psychedelic Therapies, Submitting Recommendations to FDA
globenewswire.com · Oct 7
NeuroThera Highlights Enhancement of U.S. Patent Portfolio Through Collaboration with Clearmind Covering LSD, Ketamine and Ibogaine Combinations
thenewswire.com · Sep 23
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.